The Biostatistics Core will provide essential biostatistical support to investigators on the Northwest ProstateCancer SPORE. This Core will link study design, data collection, measurement, and analysis to the criticalhypotheses and questions of the Northwest Prostate Cancer SPORE through the following Specific Aims:1. Study Design: Define study hypotheses, study populations and experimental parameters to answer theresearch questions of interest, reduce systematic bias and ensure a high likelihood of detection ofbiologically meaningful effects.2. Analysis and Interpretation: Identify and implement state-of-the-art quantitative methods to address thescientific questions of interest and provide valid statistical inferences about the evidence supporting thevarious study hypotheses. Provide necessary bioinformatics expertise for study interpretation.3. Methods Development: Where appropriate statistical methods are inadequate or lacking, devise andimplement novel quantitative approaches to address study questions of interest.During the prior funding period, the Biostatistics Core played an integral role in the collection, validation andanalysis of data for SPORE projects. Our experience has shown that involvement of statisticians from theconcept phase yields studies that are better designed, more likely to answer the scientific questions ofinterest, and, ultimately, more compelling in their conclusions. Therefore the Core will continue to functionthough close collaboration with investigators from the beginning through the life of each SPORE study.The Biostatistics Core operates from within the Biostatistics Program at the Fred Hutchinson CancerResearch Center. Investigators on the Biostatistics Core play leadership roles on funded studies andprograms whose missions overlap considerably with that of the Core. These include the Data managementand Coordinating Center for the Early Detection Research Network, and the Program in ComputationalBiology and Bioinformatics at the Fred Hutchinson Cancer Research Center. Access to and collaborationwith these programs will enhance the Core's ability to address analytic questions raised by SPORE studiesusing cutting-edge, and, if necessary, novel techniques.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097186-06
Application #
7314957
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-09-14
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$117,484
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Pollan, Sara G; Huang, Fangjin; Sperger, Jamie M et al. (2018) Regulation of inside-out ?1-integrin activation by CDCP1. Oncogene 37:2817-2836
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Schweizer, Michael T; Hancock, Michael L; Getzenberg, Robert H et al. (2018) Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian J Androl 20:405-406
Yan, Qingxiang; Bantis, Leonidas E; Stanford, Janet L et al. (2018) Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. Stat Med 37:627-642
Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167
Lam, Hung-Ming; Nguyen, Holly M; Corey, Eva (2018) Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. Methods Mol Biol 1786:1-27
Schenk, Jeannette M; Song, Xiaoling; Morrissey, Colm et al. (2018) Plasma Fatty Acids as Surrogate for Prostate Levels. Nutr Cancer 70:45-50
Beshiri, Michael L; Tice, Caitlin M; Tran, Crystal et al. (2018) A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 24:4332-4345
Das, Lipsa; Gard, Jaime M C; Prekeris, Rytis et al. (2018) Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer. Mol Cancer Res 16:1319-1331
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :

Showing the most recent 10 out of 400 publications